Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: THR004
MIFTS: 55

Thrombocytosis

Categories: Blood diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Thrombocytosis

About this section

MalaCards integrated aliases for Thrombocytosis:

Name: Thrombocytosis 12 77 30 56 45 15 74
Thrombocythaemia 12

Classifications:

MalaCards categories:
Anatomical: Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2228
MeSH 45 D013922
NCIt 51 C35530
SNOMED-CT 69 6631009 79574003
UMLS 74 C0836924
Sources

Summaries for Thrombocytosis

About this section
Disease Ontology : 12 A blood platelet disease that is characterized by the presence of high platelet counts in the blood.

MalaCards based summary : Thrombocytosis, also known as thrombocythaemia, is related to thrombocythemia 1 and polycythemia vera. An important gene associated with Thrombocytosis is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Hydroxyurea and Anagrelide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are hematopoietic system and cardiovascular system

Wikipedia : 77 Thrombocythemia (also thrombocytosis) is the presence of high platelet (thrombocyte) counts in the... more...

Sources

Related Diseases for Thrombocytosis

About this section

Diseases related to Thrombocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 402)
# Related Disease Score Top Affiliating Genes
1 thrombocythemia 1 33.2 MPL THPO
2 polycythemia vera 31.7 EPO IL3 JAK2 MPL SELP TET2
3 essential thrombocythemia 31.0 EPO F2 F3 IL11 IL3 JAK2
4 myeloproliferative neoplasm 30.6 JAK2 MPL TET2
5 refractory anemia 30.5 EPO IL3 JAK2 MPL TET2
6 splenomegaly 30.5 EPO JAK2 MPL
7 iron deficiency anemia 30.4 CRP EPO IL6 THPO
8 chromosome 5q deletion syndrome 30.3 EPO TET2
9 poems syndrome 30.3 EPO IL6
10 myeloid leukemia 30.3 CSF2 IL3 JAK2 TET2
11 thrombocytopenia 30.2 F3 IL11 MPL THPO
12 blood platelet disease 30.2 F2 F3 JAK2 MPL SELP SERPINC1
13 polycythemia 30.1 EPO IL3 JAK2 MPL TET2 THPO
14 myelodysplastic myeloproliferative cancer 30.0 CSF2 JAK2 TET2
15 myelofibrosis 30.0 EPO IL3 JAK2 MPL TET2 THPO
16 relapsing polychondritis 30.0 CRP IL6
17 portal hypertension 30.0 F2 JAK2 THPO
18 deficiency anemia 29.9 CRP EPO IL11 IL3 IL6 THPO
19 central retinal vein occlusion 29.6 F2 IL6 SERPINC1
20 retinal vein occlusion 29.6 F2 IL6 SERPINC1
21 leukemia, acute myeloid 29.6 CSF2 IL3 JAK2 MPL TET2 THPO
22 intracranial hypertension 29.5 F2 F3 SERPINC1
23 portal vein thrombosis 29.5 F2 JAK2 SELP SERPINC1
24 leukemia, chronic myeloid 29.5 CSF2 EPO IL3 JAK2 MPL THPO
25 thrombosis 29.5 F2 F3 JAK2 SELP SERPINC1
26 peritonitis 29.5 CRP F2 IL6
27 coronary artery anomaly 29.4 CRP F2 SELP
28 thrombocytopenic purpura, autoimmune 29.4 IL11 MPL SELP THPO
29 myeloma, multiple 29.4 CRP CSF2 EPO IL6 JAK2
30 thrombophilia due to thrombin defect 29.4 F2 F3 SERPINC1
31 intracranial embolism 29.4 F2 SERPINC1
32 bacterial infectious disease 29.4 CRP CSF2 IL6
33 coronary heart disease 1 29.3 CRP IL6 SELP
34 budd-chiari syndrome 29.2 F2 F3 JAK2 SERPINC1
35 sagittal sinus thrombosis 29.2 F2 F3 SERPINC1
36 nervous system disease 29.2 CRP CSF2 IL6
37 von willebrand's disease 29.2 F2 F3 SELP
38 heparin-induced thrombocytopenia 29.2 F3 SERPINC1
39 myelodysplastic syndrome 29.1 CSF2 EPO IL11 IL3 JAK2 MPL
40 acute myocardial infarction 29.1 CRP F3 SELP SERPINC1
41 pancytopenia 29.1 CSF2 EPO IL3 MPL THPO
42 megakaryocytic leukemia 29.1 CSF2 IL11 IL3 JAK2 THPO
43 monocytic leukemia 29.1 CSF2 F3 IL6
44 pulmonary embolism 29.0 CRP F2 F3 SERPINC1
45 thrombophilia due to activated protein c resistance 28.9 F2 F3 SERPINC1
46 thrombophilia 28.9 F2 F3 SERPINC1
47 myocardial infarction 28.8 CRP F2 F3 IL6 SELP SERPINC1
48 hemorrhagic disease 28.7 F2 F3 MPL SERPINC1 THPO
49 purpura 28.5 CRP F2 F3 IL6 MPL SERPINC1
50 arteries, anomalies of 28.5 CRP F3 IL6 SELP SERPINC1

Graphical network of the top 20 diseases related to Thrombocytosis:



Diseases related to Thrombocytosis
Sources

Symptoms & Phenotypes for Thrombocytosis

About this section

MGI Mouse Phenotypes related to Thrombocytosis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.14 CSF2 EPO F2 F3 IL6 JAK2
2 cardiovascular system MP:0005385 10.11 CRP CSF2 EPO F2 F3 IL6
3 homeostasis/metabolism MP:0005376 10.11 CRP CSF2 EPO F2 F3 IL6
4 immune system MP:0005387 10.1 CRP CSF2 EPO F2 F3 IL6
5 embryo MP:0005380 9.98 CSF2 EPO F2 F3 JAK2 MPL
6 integument MP:0010771 9.8 CSF2 EPO F2 F3 IL6 JAK2
7 mortality/aging MP:0010768 9.65 CSF2 EPO F2 F3 IL6 JAK2
8 liver/biliary system MP:0005370 9.63 EPO IL6 JAK2 SELP SERPINC1 TET2
9 respiratory system MP:0005388 9.1 CSF2 EPO F2 F3 IL6 SELP
Sources

Drugs & Therapeutics for Thrombocytosis

About this section

Drugs for Thrombocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 290)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxyurea Approved Phase 4,Phase 3,Phase 2,Not Applicable 127-07-1 3657
2
Anagrelide Approved Phase 4,Phase 3,Phase 2 68475-42-3 2182
3
tannic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1401-55-4
4
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
5
Lactitol Investigational Phase 4,Phase 2,Phase 3 585-86-4, 585-88-6 493591
6 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
8 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
9
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
10
Sargramostim Approved, Investigational Phase 3,Phase 1,Phase 2 123774-72-1, 83869-56-1
11
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
12
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
13
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
14
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 38904 10339178 498142
15
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
16
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 55-98-1 2478
17
Aspirin Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-78-2 2244
18
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
19
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
20
Pomalidomide Approved Phase 3,Phase 2,Phase 1 19171-19-8
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
22
Dalteparin Approved Phase 3 9005-49-6
23
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
24
Ondansetron Approved Phase 3,Phase 1,Phase 2,Not Applicable 99614-02-5 4595
25
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
26
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
27
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 2826718 468682
28
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
29
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
30
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
31
Ribavirin Approved Phase 3 36791-04-5 37542
32
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 460612 4053
33
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
34
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
35
Danazol Approved Phase 3,Phase 2 17230-88-5 28417
36
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1 147-94-4, 65-46-3 6253
37
Hydroxychloroquine Approved Phase 3 118-42-3 3652
38
Mercaptopurine Approved Phase 3 50-44-2 667490
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
40
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
41
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
42 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
43 Anesthetics Phase 3
44 Anesthetics, Dissociative Phase 3
45 Anesthetics, Intravenous Phase 3
46 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
47 Excitatory Amino Acid Antagonists Phase 3
48 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
49 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Analgesics Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 283)
# Name Status NCT ID Phase Drugs
1 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients Completed NCT00202644 Phase 4 Anagrelide;Hydroxyurea
2 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
3 Anagre Cap. in Patients With High-Risk Essential Thrombocythemia Recruiting NCT03232177 Phase 4 Anagre Cap.
4 CINC424A2X01B Rollover Protocol Recruiting NCT02386800 Phase 4 Ruxolitinib
5 Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
6 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 Anagrelide Retard in Essential Thrombocythemia Completed NCT02076815 Phase 3 Anagrelide retard;Thromboreductin
8 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
9 Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia Completed NCT01230775 Phase 3 Anagrelide retard;Placebo
10 Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Completed NCT01214915 Phase 3 Anagrelide Hydrochloride
11 Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia Completed NCT01065038 Phase 3 Anagrelide;Hydroxyurea
12 Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia Completed NCT01467661 Phase 3 SPD422 (anagrelide hydrochloride)
13 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
14 INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. Completed NCT01493414 Phase 3 INC424
15 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
16 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed NCT00934544 Phase 3 INC424/INCB018424;Best Available Therapy (BAT)
17 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3 SAR302503;Placebo
18 High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) Completed NCT00050531 Phase 3 Gleevec;Peg-alpha interferon (Peg-Intron);Sargramostim (GM-CSF)
19 Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence Completed NCT01178281 Phase 3 Pomalidomide 0.5 mg;Placebo
20 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
21 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
22 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
23 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
24 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
25 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
26 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
27 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
28 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
29 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
30 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease Completed NCT00529568 Phase 3 eltrombopag;placebo
31 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease Completed NCT00516321 Phase 3 eltrombopag;placebo
32 A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis Completed NCT00988221 Phase 3 Tocilizumab;Placebo
33 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA) Completed NCT00642460 Phase 3 tocilizumab [RoActemra/Actemra];Placebo;Non-steroidal anti-inflammatory drugs (NSAIDs);methotrexate;corticosteroids
34 Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia Recruiting NCT02611973 Phase 3 Hydroxyurea treatment (HU)
35 An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib Recruiting NCT03755518 Phase 3 FEDRATINIB
36 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Active, not recruiting NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
37 The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Active, not recruiting NCT02962388 Phase 2, Phase 3 Anagrelide;Ruxolitinib (JAKAVI®);IFNα/ PegIFNα
38 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
39 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
40 A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients Active, not recruiting NCT01621204 Phase 3 Eltrombopag;IVIG infusion
41 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
42 Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome Not yet recruiting NCT03540810 Phase 3 Hydroxychloroquine;Placebo
43 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
44 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
45 A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
46 LBH589 (Panobinostat) for the Treatment of Myelofibrosis Unknown status NCT01298934 Phase 1, Phase 2 LBH589
47 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
48 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis Completed NCT00586651 Phase 2 lestaurtinib
49 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Completed NCT01259817 Phase 2 PEGASYS;Aspirin
50 Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis Completed NCT00509899 Phase 1, Phase 2 Ruxolitinib

Search NIH Clinical Center for Thrombocytosis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: thrombocytosis

Sources

Genetic Tests for Thrombocytosis

About this section

Genetic tests related to Thrombocytosis:

# Genetic test Affiliating Genes
1 Thrombocytosis 30
Sources

Anatomical Context for Thrombocytosis

About this section

MalaCards organs/tissues related to Thrombocytosis:

42
Myeloid, Bone, Bone Marrow, Testes, Spleen, T Cells, Kidney
Sources

Publications for Thrombocytosis

About this section

Articles related to Thrombocytosis:

(show top 50) (show all 1570)
# Title Authors Year
1
The S505A thrombopoietin receptor mutation in childhood hereditary thrombocytosis and essential thrombocythemia is S505N: single letter amino acid code matters. ( 30635630 )
2019
2
GATA-1 a potential novel biomarker for the differentiation of essential thrombocythaemia and myelofibrosis. ( 30889303 )
2019
3
Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis. ( 30726782 )
2019
4
Herbaspirillum huttiense pneumonia in a patient with essential thrombocythaemia. ( 30556384 )
2019
5
The role of hepcidin, GDF15, and mitoferrin-1 in iron metabolism of polycythemia vera and essential thrombocytosis patients ( 30761871 )
2019
6
Extreme reactive thrombocytosis in an infant: Much ado about nothing? ( 30251331 )
2019
7
Approximately 1% of chronic myeloid leukaemia cases present with isolated thrombocytosis and express common major breakpoints: a finding from a laboratory audit. ( 30477881 )
2019
8
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management". ( 30618061 )
2019
9
Therapeutic thrombocytapheresis for extreme thrombocytosis after chemotherapy in essential thrombocytosis. ( 30624802 )
2019
10
Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis. ( 30646853 )
2019
11
Thrombocytosis is linked to increased cancer risk, study finds. ( 30696627 )
2019
12
Asymptomatic late thrombocytosis is a common finding in very preterm infants even in the absence of erythropoietin treatment. ( 30732496 )
2019
13
Thrombocytosis as a Predictor of Serious Bacterial Infection in Febrile Infants. ( 30739929 )
2019
14
Reactive thrombocytosis in acute infectious diseases: Prevalence, characteristics and timing. ( 30795883 )
2019
15
Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist. ( 30811101 )
2019
16
Reversible iatrogenic paraparesis secondary to masked hypokalaemia in thrombocytosis-associated pseudohyperkalaemia. ( 30904892 )
2019
17
Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms. ( 29767848 )
2019
18
The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis. ( 29654448 )
2018
19
Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies. ( 29404744 )
2018
20
Successful replantation of 2 digits in a patient with thrombocytosis after splenectomy: A case report. ( 29851840 )
2018
21
Preliminary investigation about the expression of tubulin in platelets from patients with iron deficiency anemia and thrombocytosis. ( 29499633 )
2018
22
Assessment of procoagulant potential in patients with reactive thrombocytosis and its association with platelet count. ( 29240268 )
2018
23
Essential thrombocytosis 40 years after splenectomy. ( 29602892 )
2018
24
A Rare Case of Pediatric Chronic Myelogenous Leukemia Presenting With Severe Thrombocytosis Without Leukocytosis. ( 29187020 )
2018
25
Factors associated with ultrasound-guided water enema reduction for pediatric intussusception in resource-limited setting: potential predictive role of thrombocytosis and anemia. ( 29459045 )
2018
26
Progression to polythythemia vera from familial thrombocytosis with germline JAK2 R867Q mutation. ( 29368262 )
2018
27
Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. ( 29282219 )
2018
28
Transformation of MDS/MPN-RS-T to AML: Trisomy 13, resistant thrombocytosis and transient disease control with oral busulfan therapy. ( 28984013 )
2018
29
Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts. ( 29373977 )
2018
30
Germline JAK2 L611S mutation in a child with thrombocytosis. ( 29567786 )
2018
31
Plateletpheresis: Nonoperative Management of Symptomatic Carotid Thrombosis in a Patient with Reactive Thrombocytosis. ( 29555611 )
2018
32
Platelet Characteristics in Patients with Essential Thrombocytosis. ( 29790256 )
2018
33
Spurious thrombocytosis in the setting of hemolytic anemia and microcytosis secondary to extensive burn injury. ( 29391327 )
2018
34
Thrombocytosis in a male patient with acute promyelocytic leukaemia during all-trans retinoic (ATRA) acid treatment. ( 29633731 )
2018
35
Thrombocytosis in children: Clinico-hematological profile from a single centre in Eastern India. ( 29403202 )
2018
36
The pretreatment thrombocytosis as one of prognostic factors for gastric cancer: A systematic review and meta-analysis. ( 29654963 )
2018
37
Successful replantation of 2 digits in a patient with thrombocytosis after splenectomy: A case report: Erratum. ( 29979453 )
2018
38
Jak-2 mutation frequency in patients with thrombocytosis. ( 29732039 )
2018
39
Integrated micro/messenger RNA regulatory networks in essential thrombocytosis. ( 29420626 )
2018
40
Preoperative SCC-Ag and thrombocytosis as predictive markers for pelvic lymphatic metastasis of squamous cervical cancer in early FIGO stage. ( 29760805 )
2018
41
Pediatric Chronic Myeloid Leukemia Presenting With Extreme Thrombocytosis Simulating Essential Thrombocythemia. ( 29668550 )
2018
42
Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. ( 29442537 )
2018
43
Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). ( 29067707 )
2018
44
Therapeutic Thrombocytapheresis for Symptomatic Thrombocytosis in Hemato-Oncology Patients. ( 29205870 )
2018
45
Aggregometry in the settings of thrombocytopenia, thrombocytosis and antiplatelet therapy. ( 29537938 )
2018
46
Is thrombocytosis always an indicator of autosplenectomy in patients with systemic lupus erythematosus? ( 29119304 )
2018
47
Marked rebound thrombocytosis in response to glucocorticoids in a patient with acquired amegakaryocytic thrombocytopenia. ( 30416171 )
2018
48
The prognostic role of pretreatment thrombocytosis in gastric cancer: A systematic review and meta-analysis. ( 30075601 )
2018
49
Coexpression of ETV6/MDS1/EVI1 and ETV6/EVI1 fusion transcripts in acute myeloid leukemia with t(3;12)(q26.2;p13) and thrombocytosis. ( 30526151 )
2018
50
Chronic Myeloid Leukemia with b3a3 (e14a3) Fusion: A Rare BCR/ABL Rearrangement Presenting with Thrombocytosis - Does MTHFR Polymorphism Matter. ( 30140211 )
2018
Sources

Variations for Thrombocytosis

About this section
Sources

Expression for Thrombocytosis

About this section
Search GEO for disease gene expression data for Thrombocytosis.
Sources

Pathways for Thrombocytosis

About this section

Pathways related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
PEDF Induced Signaling 65
Show member pathways
 13.43 CSF2 EPO F2 IL11 IL3 IL6
2
TGF-Beta Pathway 65
Show member pathways
 13.36 EPO F2 IL11 IL3 IL6 JAK2
3
Akt Signaling 65
Show member pathways
 13.25 CSF2 IL11 IL3 IL6 JAK2 THPO
4
PAK Pathway 65
Show member pathways
 13.13 CSF2 IL11 IL3 IL6 JAK2 THPO
5
Response to elevated platelet cytosolic Ca2+ 67
Show member pathways
 12.99 CSF2 F2 F3 IL3 JAK2 MPL
6
p70S6K Signaling 65
Show member pathways
 12.89 F2 IL3 IL6 JAK2 THPO
7
Kit receptor signaling pathway 1
Show member pathways
 12.03 EPO IL3 JAK2
8
Formation of Fibrin Clot (Clotting Cascade) 67
Show member pathways
 12.02 F2 F3 SERPINC1
9
G beta-gamma signalling through PI3Kgamma 67
Show member pathways
 12 CSF2 IL3 JAK2
10
Complement and coagulation cascades 38 1
11.95 F2 F3 SERPINC1
11
Immune response IFN gamma signaling pathway 23
Show member pathways
 11.95 IL11 IL3 IL6 JAK2 THPO
12
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.94 IL11 IL3 IL6 THPO
13
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 11.92 CSF2 EPO IL11 IL3 IL6 JAK2
14
Microglia Activation During Neuroinflammation: Overview 66
Show member pathways
 11.89 CSF2 F2 IL6
15
AGE-RAGE signaling pathway in diabetic complications 38
11.78 F3 IL6 JAK2
16
Integrin alphaIIb beta3 signaling 67
Show member pathways
 11.77 F2 MPL THPO
17
Jak-Stat Signaling Pathway (sino) 68
11.74 EPO IL3 IL6 JAK2
18
Cytokine production by Th17 cells in CF (Mouse model) 23
Show member pathways
 11.73 CSF2 IL6 JAK2
19
Visual Cycle in Retinal Rods 65
11.73 CRP JAK2 MPL THPO
20
Rheumatoid arthritis 38
11.71 CSF2 IL11 IL6
21
Hematopoietic cell lineage 38
11.62 CSF2 EPO IL11 IL3 IL6 THPO
22
Interleukin-6 family signaling 67
Show member pathways
 11.5 IL11 IL6 JAK2
23
Differentiation Pathway 1
11.39 EPO IL11 IL3 IL6
24
Hematopoietic Stem Cell Differentiation 1
11.35 CSF2 EPO IL3 IL6
25
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.23 CSF2 EPO IL11 IL3 IL6 MPL
26
Development_Thrombopoetin signaling via JAK-STAT pathway 23
11.14 CRP JAK2 MPL THPO
27
Cytokines and Inflammatory Response 1
11.09 CSF2 IL11 IL3 IL6
28
G-protein signaling_RhoB regulation pathway 23
11.08 CSF2 IL11 IL3 IL6
29
Overview of nanoparticle effects 1
10.9 CRP IL6
30
G-protein signaling_Rap2B regulation pathway 23
10.87 CSF2 IL11 IL3 IL6 THPO
Sources

GO Terms for Thrombocytosis

About this section

Cellular components related to Thrombocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CRP CSF2 EPO F2 F3 IL11
2 extracellular space GO:0005615 9.36 CRP CSF2 EPO F2 F3 IL11

Biological processes related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.8 CSF2 EPO F2 IL11 IL3 IL6
2 blood coagulation GO:0007596 9.73 F2 F3 JAK2 SERPINC1
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 IL11 IL3 IL6 JAK2
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.65 F2 JAK2 SELP
5 hemostasis GO:0007599 9.63 F2 F3 SERPINC1
6 acute-phase response GO:0006953 9.62 CRP EPO F2 IL6
7 positive regulation of cell proliferation GO:0008284 9.56 CSF2 EPO F2 IL11 IL3 IL6
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.55 CSF2 EPO IL3 IL6 JAK2
9 myeloid cell differentiation GO:0030099 9.54 TET2 THPO
10 interleukin-6-mediated signaling pathway GO:0070102 9.52 IL6 JAK2
11 regulation of blood coagulation GO:0030193 9.51 F2 SERPINC1
12 negative regulation of lipid storage GO:0010888 9.49 CRP IL6
13 thrombopoietin-mediated signaling pathway GO:0038163 9.4 MPL THPO
14 cytokine-mediated signaling pathway GO:0019221 9.17 CSF2 F3 IL11 IL3 IL6 JAK2

Molecular functions related to Thrombocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 CSF2 EPO IL11 IL3 IL6 THPO
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.33 CSF2 IL3 JAK2
3 growth factor activity GO:0008083 9.1 CSF2 F2 IL11 IL3 IL6 THPO
Sources

Sources for Thrombocytosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....